Clinical trial
Prevention of Graft-Versus-Host Disease in Patients With Hematologic…
NCT00002790 · Fred Hutchinson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00002790 |
|---|---|
| Title | Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant |
| Official title | A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIGEN IN THE DIRECTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | cyclosporine, methotrexate, sirolimus |
| Enrollment | 0 |
| Start date | Mar 1, 1996 |
| First posted | Sep 2, 2004 |
| Last update posted | Mar 6, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: